Erlacher L, Wyatt J, Pflugbeil S, Köller M, Ullrich R, Vogelsang H, Smolen J S, Graninger W
Department of Internal Medicine III, University of Vienna, Austria.
Clin Exp Rheumatol. 1998 Jan-Feb;16(1):69-71.
To evaluate sucrose permeability as a non-invasive test for the monitoring of upper gastrointestinal mucosal damage (uGMD) in patients treated with NSAIDs.
40 patients with non-inflammatory joint pain were enrolled in a prospective study. Before and after 14 days of ibuprofen treatment (3 x 400 mg/day), the rates of urinary sucrose excretion after an oral sucrose load were assessed. Individuals with increased sucrose permeability underwent endoscopy.
8 patients (20%) showed abnormal sucrose permeability before taking any NSAID. In 5/20 patients (25%) who completed 2 weeks of ibuprofen medication, sucrose excretion increased above the normal level. Endoscopic examination and biopsy revealed mild uGMD, but no ulceration in 8/11 (72%) patients with increased permeability to this marker.
Sucrose permeability testing is a sensitive procedure for research protocols on NSAID-induced gastropathy. Since this test also seems to detect slight and clinically insignificant mucosal damage, however, its use in clinical decision-making regarding gastroprotective medication is limited.
